Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough

Authors:	Athanasios D. Anastasilakis Georgios Trovas Alexia Balanika Stergios A. Polyzos Polyzois Makras Symeon Tournis

Affiliation:	1. Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece;2. Laboratory for the Research of Musculoskeletal System “Th. Garofalidis,” Medical School, National and Kapodistrian University of Athens, KAT Hospital, Greece;3. Department of Computed Tomography, Asklepeion Voulas Hospital, Athens, Greece;4. First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece;5. Department of Endocrinology and Diabetes and Department of Medical Research, 251 Hellenic Airforce and VA Hospital, Athens, Greece;1. Center for Clinical Investigation, Brigham & Women''s Hospital, Boston, MA, USA;2. Department of Preventive and Community Dentistry, University of Iowa College of Dentistry, Iowa City, IA, USA;3. Department of Epidemiology, University of Iowa College of Public Health, Iowa City, IA, USA;4. Department of Health and Human Physiology, College of Liberal Arts and Sciences, University of Iowa, Iowa City, IA, USA;5. Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, USA;6. Department of Biostatistics, University of Iowa College of Public Health, Iowa City, IA, USA;7. Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA;8. Department of Oral Biology, School of Dental Medicine, University of Pittsburgh, Pittsburgh, PA, USA;9. Center for Craniofacial and Dental Genetics, Department of Oral Biology, School of Dental Medicine, University of Pittsburgh, Pittsburgh, PA, USA;10. Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA;11. Clinical and Translational Science, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA;12. Department of Epidemiology, University of Iowa College of Public Health, Iowa City, IA, USA;1. Department of Epidemiology and Population Sciences, University of Hawaii Cancer Center, Honolulu, HI, USA;2. Department of Bones & Joints, Center of Bone Diseases, Lausanne University Hospital, Lausanne, Switzerland;3. Medimaps Group, Geneva, Switzerland;1. Department of Physical Education, Division of Education, Faculty of Arts and Sciences, University of Balamand, Kelhat El-Koura, Lebanon;2. EA 7369 - URePSSS - unité de recherche pluridisciplinaire sport santé société, Université Littoral Côte d''Opale, France;3. Laboratoire Mouvement, Equilibre, Performance, Santé (MEPS, EA-4445), Université de Pau et des Pays de l''Adour, Tarbes, France

Abstract:	Rebound-associated vertebral fractures (RAVFs) could occur in a minority of the patients who discontinue denosumab. In such patients, denosumab is often reinstituted to rapidly suppress bone turnover and avert the risk of additional fractures. Herein we report the cases of 2 patients who sustained RAVFs, and in whom resuming denosumab treatment did not avert the occurrence of new RAVFs a few months later, despite the suppression of bone turnover markers. It seems that denosumab reinstitution cannot completely eliminate the risk of new RAVFs and that the rebound of bone turnover may not be the sole mechanism to explain this phenomenon.

Keywords:
本文献已被 ScienceDirect 等数据库收录！

设为首页 | 免责声明 | 关于勤云 | 加入收藏